Extended spectrum β-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors

Indian Journal of Medical Research

Volumn 129, Issue 6, 2009, Pages 695-700

  Goyal, Ankur ^a   Prasad, Kashi N ^a   Prasad, Amit ^a   Gupta, Sapna ^a   Ghoshal, Ujjala ^a   Ayyagari, Archana ^b  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

CTX M; Drug resistance; ESBL; Escherichia coli; Klebsiella pneumoniae; Risk factor

Indexed keywords

AMIKACIN; BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 1; BETA LACTAMASE CTX M 3; BETA LACTAMASE SHV; BETA LACTAMASE TEM; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; HYDROLASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIUM ISOLATE; BLADDER CATHETERIZATION; CHILD; DRUG EXPOSURE; ENZYME ASSAY; ENZYME SYNTHESIS; ESCHERICHIA COLI; FEMALE; GENE IDENTIFICATION; GENE SEQUENCE; GENOTYPE; HOSPITAL INFECTION; HUMAN; INFANT; INFECTION RISK; INTENSIVE CARE UNIT; INTRAVENOUS ADMINISTRATION; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MOLECULAR TYPING; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; TERTIARY HEALTH CARE;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENOTYPE; HOSPITALS; HUMANS; INFANT; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 70349548630     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
2. Emery CL, Weymouth LA. Detection and clinical significance of extended- spectrum β-lactamases in a tertiary-care medical center. J Clin Microbiol 1997; 35: 2061-7.
3. Paterson DL, Bonomo RA. Extended spectrum β-lactamases: a clinical update. Clin Microbial Rev 2005; 18: 657-86.
4. Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
5. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S16 16th informational supplement. Clinical and Laboratory Standards Institute, Wayne, Pa; 2006.
6. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-78.
7. Sambrook J, Fritsch EF, Miniatis T. Extraction and purification of plasmid DNA. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 1989. p. 1.32-1.34.
8. Edelstein M, Pimkin M, Palagin I, Edelstein I, Stratchounski L. Prevalence and molecular epidemiology of CTX-M extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob Agents Chemother 2003; 47: 3724-32.
9. Lee SH, Kim JY, Lee SK, Jin W, Kang SG, Lee KJ. Discriminatory detection of extended-spectrum β-lactamases by restriction fragment length dimorphism- polymerase chain reaction. Lett Appl Microbiol 2000; 31: 307-12.
10. Sanger F, Nicklen S, Coulson AP. DNA sequencing with chain terminating inhibitors. Proc Naltl Acad Sci USA 1977; 74: 7463-7.
11. Grover SS, Sharma M, Chattopadhya D, Kapoor H, Pasha ST, Singh G. Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in Klebsiella pneumoniae: emergence of high resistance against cefepime, the fourth generation cephalosporin. J Infect 2006; 53: 279-88.
12. Jain A, Roy I, Gupta MK, Kumar M, Agarwal SK. Prevalence of extended-spectrum β-lactamase-producing Gram-negative bacteria in septicaemic neonates in a tertiary care hospital. J Med Microbiol 2003; 52: 421-5.
13. Lal P, Kapil A, Das BK, Sood S. Occurrence of TEM & SHV gene in extended spectrum β-lactamases (ESBLs) producing Klebsiella sp. isolated from a tertiary care hospital. Indian J Med Res 2007; 125: 173-8.
14. Pournaras S, Ikonomidis A, Kristo I, Tsakris A, Maniatis AN. CTX-M enzymes are the most common extended-spectrum β-lactamases among Escherichia coli in a tertiary Greek hospital. J Antimicrob Chemother 2004; 54: 574-5.
15. Brenwald NP, Jevons G, Andrews JM, Xiong JH, Hawkey PM, Wise R. An outbreak of a CTX-M-type β-lactamase-producing Klebsiella pneumoniae: the importance of using cefpodoxime to detect extended-spectrum β-lactamases. J Antimicrob Chemother 2003; 51: 195-6.
16. Mugnaioli C, Luzzaro F, De Luca F, Brigante G, Perilli M, Amicosante G, et al. CTX-M-type extended-spectrum β-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother 2006; 50: 2700-6.
17. Ensor VM, Shahid M, Evans JT, Hawkey PM. Occurrence, prevalence and genetic environment of CTX-M β-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 2006; 58: 1260-3.
18. Karim A, Poirel L, Nagarajan S, Nordmann P. Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett 2001; 201: 237-41.
19. Baraniak A, Fiett J, Sulikowska A, Hryniewicz W, Gniadkowski M. Countrywide spread of CTX-M-3 extended-spectrum β-lactamase producing microorganisms of the family Enterobacteriaceae in Poland. Antimicrob Agents Chemother 2002; 46: 151-9.
20. Petroni A, Corso A, Melano R, Cacace ML, Bru AM, Rossi A, et al. Plasmidic extended-spectrum β-lactamases in Vibrio cholerae O1 El Tor isolates in Argentina. Antimicrob Agents Chemother 2002; 46: 1462-8.
21. Yagi T, Kurokawa H, Shibata N, Shibayama K, Arakawa Y. A preliminary survey of extended-spectrum β-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett 2000; 184: 53-6.
22. Miro E, del Cuerpo M, Navarro F, Sabate M, Mirelis B, Prats G. Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction. J Antimicrob Chemother 1998; 42: 535-8.
23. Subha A, Ananthan S, Alavandi SV. Extended spectrum betalactamase production & multidrug resistance in Klebsiella species isolated from children under five with intestinal & extraintestinal infections. Indian J Med Res 2001; 113: 181-5.
24. Luzzaro F, Mezzatesta M, Mugnaioli C, Perilli M, Stefani S, Amicosante G, et al. Trends in production of extendedspectrum β-lactamases among Enterobacteria of medical interest: report of the second Italian nationwide survey. J Clin Microbiol 2006; 44: 1659-64.
25. Graffunder EM, Preston KE, Evans AM, Venezia RA. Risk factors associated with extended-spectrum β-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother 2005; 56: 139-45.
26. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-71.